Cytotoxic Drugs Market size is expected to be valued at USD 15,927.2 million in 2022, growing at a significant CAGR of 2.2% during 2022–2028. Cytotoxic drugs, also known as antineoplastics, are a group of medicines that contain toxic chemicals to cells, preventing their replication or growth. They are widely used to treat various cancers and other disorders, such as rheumatoid arthritis and multiple sclerosis. Cytotoxic drugs can destroy tumors and reduce metastases and lessen cancer symptoms. Cancer cells replicate faster than normal cells, making them susceptible to cytostatics. The effects on normal cells are less pronounced, and healthy cells recover faster. The increasing prevalence of various types of cancer, such as leukemia, breast cancer, etc, is the major driver in the global cytotoxic drugs market growth. According to the World Health Organization, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The most common cancer in 2020 was breast cancer (2.26 million cases), lung (2.21 million cases), etc. Moreover, increasing use and approval of cytotoxic drugs are also expected to boost the global cytotoxic drugs market growth. Also, the growing therapeutic area of cytotoxic drugs in auto-immune conditions such as rheumatoid arthritis, psoriasis, or prevention of transplant rejection is influencing the overall cytotoxic market growth. However, the adverse side effects of the consumption of cytotoxic drugs, such as nausea and vomiting, severe diarrhea, and damage to normal cells and tissue, are restraining the global cytotoxic drugs market growth. Based on the product type, the global cytotoxic market is segmented into alkylating agents, antitumor antibiotics, antimetabolites, plant alkaloids, and others. The antimetabolites segment held the major global cytotoxic drugs market revenue in 2021. Geographically, North America held the major market share in the global cytotoxic drugs market and is expected to dominate the global market in the forecasted years.
Recent Market Developments:
In Sept 2022, FDA cleared AstraZeneca’s Imfinzi to treat locally advanced or metastatic biliary tract cancer, making it the first immunotherapy-based treatment option for this aggressive cancer type.
In May 2022, Pfizer announced Asia’s first global drug development center at IIT Madras Research Park.